Top

BMC Cancer

Published in:

Open Access 01-12-2021 | Glioblastoma | Research article

Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies

Authors: Michael T. C. Poon, Morgan Bruce, Joanne E. Simpson, Cathal J. Hannan, Paul M. Brennan

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Malignant glioma cell line models are integral to pre-clinical testing of novel potential therapies. Accurate prediction of likely efficacy in the clinic requires that these models are reliable and consistent. We assessed this by examining the reporting of experimental conditions and sensitivity to temozolomide in glioma cells lines.

Methods

We searched Medline and Embase (Jan 1994-Jan 2021) for studies evaluating the effect of temozolomide monotherapy on cell viability of at least one malignant glioma cell line. Key data items included type of cell lines, temozolomide exposure duration in hours (hr), and cell viability measure (IC₅₀).

Results

We included 212 studies from 2789 non-duplicate records that reported 248 distinct cell lines. The commonest cell line was U87 (60.4%). Only 10.4% studies used a patient-derived cell line. The proportion of studies not reporting each experimental condition ranged from 8.0–27.4%, including base medium (8.0%), serum supplementation (9.9%) and number of replicates (27.4%). In studies reporting IC₅₀, the median value for U87 at 24 h, 48 h and 72 h was 123.9 μM (IQR 75.3–277.7 μM), 223.1 μM (IQR 92.0–590.1 μM) and 230.0 μM (IQR 34.1–650.0 μM), respectively. The median IC₅₀ at 72 h for patient-derived cell lines was 220 μM (IQR 81.1–800.0 μM).

Conclusion

Temozolomide sensitivity reported in comparable studies was not consistent between or within malignant glioma cell lines. Drug discovery science performed on these models cannot reliably inform clinical translation. A consensus model of reporting can maximise reproducibility and consistency among in vitro studies.

Available only for authorised users

GBD. Brain and other CNS Cancer collaborators (2019) global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2016;18(4):376–93. https://doi.org/10.1016/S1474-4422(18)30468-X.CrossRef

Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013-2017. Neuro-Oncology. 2020;22:iv1–iv96.CrossRefPubMedPubMedCentral

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol (Berl). 2016;131(6):803–20. https://doi.org/10.1007/s00401-016-1545-1.CrossRef

Poon MTC, Sudlow CLM, Figueroa JD, Brennan PM. Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci Rep. 2020;10(1):11622. https://doi.org/10.1038/s41598-020-68011-4.CrossRefPubMedPubMedCentral

Brodbelt A, Greenberg D, Winters T, Williams M, Vernon S. Collins VP, (UK) National Cancer Information Network Brain Tumour Group (2015) glioblastoma in England: 2007-2011. Eur J Cancer Oxf Engl. 1990;51(4):533–42. https://doi.org/10.1016/j.ejca.2014.12.014.CrossRef

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96. https://doi.org/10.1056/NEJMoa043330.CrossRefPubMed

Taslimi S, Ye VC, Zadeh G. Lessons learned from contemporary glioblastoma randomized clinical trials through systematic review and network meta-analysis: part 2 newly diagnosed disease. Neuro Oncol Adv. 2021;3:vdab028.CrossRef

ATCC ATCC: The Global Bioresource Center. https://www.atcc.org/. Accessed 23 Jun 2021.

Ledur PF, Onzi GR, Zong H, Lenz G. Culture conditions defining glioblastoma cells behavior: what is the impact for novel discoveries? Oncotarget. 2017;8(40):69185–97. https://doi.org/10.18632/oncotarget.20193.CrossRefPubMedPubMedCentral

10.

Robertson FL, Marqués-Torrejón M-A, Morrison GM, Pollard SM. Experimental models and tools to tackle glioblastoma. Dis Model Mech. 2019;12:dmm040386.CrossRefPubMedPubMedCentral

11.

Altman DG, Simera I. A history of the evolution of guidelines for reporting medical research: the long road to the EQUATOR network. J R Soc Med. 2016;109(2):67–77. https://doi.org/10.1177/0141076815625599.CrossRefPubMedPubMedCentral

12.

Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18:e3000410.CrossRefPubMedPubMedCentral

13.

Beier D, Schriefer B, Brawanski K, Hau P, Weis J, Schulz JB, et al. Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. J Neuro-Oncol. 2012;109(1):45–52. https://doi.org/10.1007/s11060-012-0878-4.CrossRef

14.

Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391–403. https://doi.org/10.1016/j.ccr.2006.03.030.CrossRefPubMed

15.

Peng D, Gleyzer R, Tai W-H, Kumar P, Bian Q, Isaacs B, et al. Evaluating the transcriptional fidelity of cancer models. Genome Med. 2021;13(1):73. https://doi.org/10.1186/s13073-021-00888-w.CrossRefPubMedPubMedCentral

16.

Allen M, Bjerke M, Edlund H, Nelander S, Westermark B. Origin of the U87MG glioma cell line: good news and bad news. Sci Transl Med. 2016;8:354re3.CrossRefPubMed

17.

American Type Culture Collection Standards Development Organization Workgroup ASN-0002. Cell line misidentification: the beginning of the end. Nat Rev Cancer. 2010;10(6):441–8. https://doi.org/10.1038/nrc2852.CrossRef

18.

Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009;4(6):568–80. https://doi.org/10.1016/j.stem.2009.03.014.CrossRefPubMed

19.

deCarvalho AC, Kim H, Poisson LM, et al. Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma. Nat Genet. 2018;50(5):708–17. https://doi.org/10.1038/s41588-018-0105-0.CrossRefPubMedPubMedCentral

20.

Xie Y, Bergström T, Jiang Y, Johansson P, Marinescu VD, Lindberg N, et al. The human glioblastoma cell culture resource: validated cell models representing all molecular subtypes. EBioMedicine. 2015;2(10):1351–63. https://doi.org/10.1016/j.ebiom.2015.08.026.CrossRefPubMedPubMedCentral

21.

Plumb JA, Milroy R, Kaye SB. Effects of the pH dependence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res. 1989;49(16):4435–40.PubMed

22.

Geraghty RJ, Capes-Davis A, Davis JM, Downward J, Freshney RI, Knezevic I, et al. Guidelines for the use of cell lines in biomedical research. Br J Cancer. 2014;111(6):1021–46. https://doi.org/10.1038/bjc.2014.166.CrossRefPubMedPubMedCentral

23.

Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332.CrossRefPubMedPubMedCentral

24.

CONSORT Consort - Impact of CONSORT. http://www.consort-statement.org/about-consort/impact-of-consort. Accessed 23 Jun 2021.

25.

Aquilanti E, Miller J, Santagata S, Cahill DP, Brastianos PK. Updates in prognostic markers for gliomas. Neuro-Oncology. 2018;20:vii17–26.CrossRefPubMedPubMedCentral

26.

Torsvik A, Stieber D, Enger PØ, Golebiewska A, Molven A, Svendsen A, et al. U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells. Cancer Med. 2014;3(4):812–24. https://doi.org/10.1002/cam4.219.CrossRefPubMedPubMedCentral

Title: Temozolomide sensitivity of malignant glioma cell lines – a systematic review assessing consistencies between in vitro studies
Authors: Michael T. C. Poon
Morgan Bruce
Joanne E. Simpson
Cathal J. Hannan
Paul M. Brennan
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Glioblastoma
Glioma
Glioma
Glioblastoma
Glioblastoma
Glioma
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08972-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Identification of key genes and pathways associated with resting mast cells in meningioma

High-intensity interval training in breast cancer survivors: a systematic review

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer

Comparison of clinicopathological features and long-term prognosis between mixed predominantly differentiated-type and pure differentiated-type early gastric cancer

Oral cancer knowledge and screening behavior among smokers and non-smokers in rural communities

A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer